Jaguar Health’s Napo Pharmaceuticals issues Hong Kong patent for SBS treatment

Jaguar Health announced that Hong Kong’s Intellectual Property Department has issued a new patent to Jaguar family company Napo Pharmaceuticals for methods for treating short bowel syndrome, bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar’s novel plant-based prescription drug. “We are very happy that this patent has been issued and believe that it further enhances our intellectual property protection for crofelemer for our core rare disease target indication of SBS,” said Lisa Conte, CEO. “As previously announced, Jaguar, with strong leadership and participation from Jaguar family companies Napo and Napo Therapeutics, is supporting independent investigator-initiated proof-of-concept studies of crofelemer for SBS with intestinal failure and MVID in the US, EU and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025. In accordance with the guidelines of specific EU countries, published data from clinical investigations in SBS and MVID could support early patient access to crofelemer for these debilitating conditions in those countries.”